Upstream Bio (UPB) Consolidated Net Income (2023 - 2026)

Upstream Bio's Consolidated Net Income history runs 4 years deep, the most recent figure standing at -$61.8 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 77.23% year-over-year to -$61.8 million; the TTM figure through Mar 2026 stood at -$484.0 million (down 146.9% YoY), while the FY2025 annual figure was -$305.7 million, down 123.29% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$61.8 million, up from -$204.8 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$7.9 million in Q3 2023, with the low at -$204.8 million in Q4 2025.
• The 4-year median for Consolidated Net Income is -$52.5 million (2023), against an average of -$68.7 million.
• Peak annual rise in Consolidated Net Income reached 76.19% in 2024, while the deepest fall reached 549.96% in 2024.
• Upstream Bio's Consolidated Net Income stood at -$52.5 million in 2023, then slumped by 76.19% to -$92.5 million in 2024, then plunged by 121.38% to -$204.8 million in 2025, then jumped by 69.83% to -$61.8 million in 2026.
• Business Quant data shows UPB's Consolidated Net Income at -$61.8 million in Q1 2026, -$204.8 million in Q4 2025, and -$133.3 million in Q3 2025.